Personal CFO Solutions LLC Sells 69 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Personal CFO Solutions LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 779 shares of the pharmaceutical company’s stock after selling 69 shares during the period. Personal CFO Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $274,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in VRTX. Independence Bank of Kentucky acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $25,000. Sandy Spring Bank grew its stake in shares of Vertex Pharmaceuticals by 1,014.3% in the 1st quarter. Sandy Spring Bank now owns 78 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 71 shares during the period. Marquette Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $27,000. Quent Capital LLC grew its stake in shares of Vertex Pharmaceuticals by 91.1% in the 2nd quarter. Quent Capital LLC now owns 86 shares of the pharmaceutical company’s stock valued at $30,000 after buying an additional 41 shares during the period. Finally, Altshuler Shaham Ltd acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $30,000. 90.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Sanford C. Bernstein lifted their price target on Vertex Pharmaceuticals from $380.00 to $390.00 and gave the company an “outperform” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus lifted their price target on Vertex Pharmaceuticals from $340.00 to $373.00 and gave the company a “hold” rating in a research note on Tuesday, November 7th. Canaccord Genuity Group lifted their price target on Vertex Pharmaceuticals from $312.00 to $315.00 and gave the company a “hold” rating in a research note on Monday, August 7th. HC Wainwright lifted their price target on Vertex Pharmaceuticals from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. Finally, StockNews.com upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 21st. Seven investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $376.13.

Vertex Pharmaceuticals Trading Up 1.8 %

NASDAQ:VRTX opened at $356.84 on Tuesday. The company has a current ratio of 4.08, a quick ratio of 3.89 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $91.95 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 2.28 and a beta of 0.45. The firm’s 50 day moving average is $360.48 and its 200 day moving average is $350.73. Vertex Pharmaceuticals Incorporated has a 12 month low of $282.21 and a 12 month high of $387.42.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 6th. The pharmaceutical company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $3.53 by $0.55. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 35.94% and a return on equity of 22.79%. Vertex Pharmaceuticals’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.62 EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 13.61 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $355.00, for a total transaction of $887,500.00. Following the sale, the executive vice president now owns 48,637 shares of the company’s stock, valued at approximately $17,266,135. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $355.00, for a total transaction of $887,500.00. Following the sale, the executive vice president now owns 48,637 shares of the company’s stock, valued at approximately $17,266,135. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce I. Sachs sold 11,250 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $385.00, for a total transaction of $4,331,250.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $15,400,000. The disclosure for this sale can be found here. Insiders have sold 50,411 shares of company stock valued at $18,511,525 in the last 90 days. 0.40% of the stock is currently owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.